论文部分内容阅读
氨苯砜是1908年由Fromin和Wittman研制成的。1943年Faget首先报告应用氨苯砜的衍化物——普洛明治疗麻风,疗效满意。1947年Cochrane等对氨苯砜进行研究,确定较低剂量对麻风病的治疗与其衍化物同样有效,且毒性亦低,再加上价格低廉,口服简便等优点,便在世界各地普遍推广使用。目前国际上公认氨苯砜是治疗麻风病的首选药物。 1953年Wolcott报道一些麻风病人在使用充分砜类药治疗的情况下,病情无进步,产生耐砜类药麻风的初步印象。1959年 Cochrane和1960年Pettit也先后提出麻风病人对砜类药产生耐药性的问题。1964年Pettit等根据临床并使用鼠足垫技术的实验方法,证实三名瘤型病人对氨苯砜产生肯定的耐药性。以后又有证实100例耐砜类药
Dapsone was developed in 1908 by Fromin and Wittman. In 1943 Faget first reported the application of dapsone derivate - Pluriden treatment of leprosy, with satisfactory results. Cochrane and other studies on dapsone in 1947 to determine the lower dose of leprosy treatment and its derivatives are equally effective, and the toxicity is also low, coupled with cheap, easy to oral and other advantages, it is widely used throughout the world. Dapsone is internationally recognized as the drug of choice for the treatment of leprosy. In 1953, Wolcott reported that some leprosy patients did not make any progress when using sufficient sulfone drugs, giving an initial impression of the sulfone-resistant leprosy. Cochrane in 1959 and Pettit in 1960 also raised the question of the drug resistance of leprosy to sulfone drugs. In 1964, Pettit et al. Confirmed the clinical resistance of dapsone to three patients with benign tumors based on clinical and experimental methods using mouse footpads. Since then confirmed 100 cases of sulfone drugs